Rare Cancers Australia and Cancer Australia join forces to advance genomics and precision medicine

Rare Cancers Australia (RCA) and Cancer Australia have cemented a pivotal partnership through a formalised agreement, aimed at delivering key programs under the Australian Cancer Plan. This collaboration is set to improve outcomes and experiences for people with rare cancers by addressing critical gaps in care and support.

Launched in late 2023, The Plan is Australia’s first national initiative designed to enhance cancer outcomes and tackle inequities for all individuals living with cancer across the country. With $750 million in backing, the ten-year initiative focuses on six strategic objectives that are poised to reshape cancer services and patient outcomes.

As part of this collaboration, RCA will contribute to the development of the National Framework for Genomics in Cancer Control, a crucial element in expanding access to genomic-led care for those with rare cancers. Additionally, both organisations will work together to enhance data collection and reporting through the National Cancer Data Framework, ensuring that data on rare cancers is both accessible and actionable.

RCA CEO Christine Cockburn emphasised the significance of the partnership, noting the collective effort between the government and the community in fighting inequity.

“The Australian Cancer Plan’s success relies on collaboration and action across the health sector and communities. We are pleased to be working closely with Cancer Australia, in strong stead with other patient organisations, to ensure the needs and experiences of people with rare and less common cancers are heard, understood, and addressed,” said Cockburn.

Cancer Australia CEO Professor Dorothy Keefe echoed this sentiment, underscoring the importance of partnerships in achieving the Plan’s ambitious goals.

“The Australian Cancer Plan is designed to ensure every Australian, including those with rare and less common cancers, receives the best possible care. Rare Cancers Australia is a vital partner to implement the goals and actions of the Australian Cancer Plan, and our partnership is a crucial step towards addressing the unique challenges faced by those affected by rare and less common cancers.”

Together, the organisations are driving forward initiatives such as the National Framework for Genomics in Cancer Control, advancing precision medicine, and refining national cancer data collection through the National Cancer Data Framework.

“Our shared commitment strengthens cancer care and brings us closer to equitable outcomes for all Australians affected by cancer,” Professor Keefe concluded.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.